Researchers Identified New Antibiotic for Drug-Resistant TB
A natural soil compound has shown the ability to kill drug-resistant tuberculosis by trapping its DNA repair enzyme.
Updated on Sept. 23, 2026 in Life Sciences
Live Poll
Do you believe natural compound research is the most promising path to curing drug-resistant diseases?
Researchers have identified corramycin, a natural compound derived from soil bacteria, as a potential new agent against drug-resistant Mycobacterium tuberculosis. The study marks a research-stage advancement in targeting strains that have become resistant to traditional fluoroquinolones.
Why it matters
Tuberculosis affects 10 million people annually, and current antibiotic options have limited efficacy against increasingly resistant strains. This discovery provides a new chemical mechanism to disrupt bacterial replication, addressing a critical need for alternative treatment pathways.
Corramycin functions by binding to DNA gyrase, an enzyme that cuts DNA, at a point after the cleavage has occurred. By preventing the enzyme from rejoining these DNA strands, the compound effectively traps the bacteria in a state of terminal genetic damage.
The players
HIPS
The Helmholtz Institute for Pharmaceutical Research Saarland focuses on the discovery and development of new anti-infectives.
Institut Pasteur
A Paris-based foundation globally recognized for its long-standing research into infectious diseases and microbiology.
Université Paris Cité
A research-intensive university in France contributing to interdisciplinary studies in health and life sciences.
The details
Using cryo-electron microscopy—a technique that uses electron beams to image biological samples at atomic resolution—researchers visualized how corramycin interferes with the bacterial replication machinery. The compound stabilizes the complex after DNA gyrase has initiated a cut in the double helix. Because the enzyme cannot release the DNA strands, the bacterial genetic material remains severed, leading to rapid cell death.
Timeline
September 23, 2026: Research findings were published in Advanced Science.
2009: The Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) was founded.
The Tech Race
This discovery attempts to overcome the efficacy limits of fluoroquinolones, a class of antibiotics that has seen widespread resistance in clinical settings. It follows a pattern of academic research programs seeking novel natural products to bypass established bacterial defense mechanisms.
This development is currently in the research stage and does not change clinical treatment protocols for patients today. Future availability depends on successfully optimizing the compound's pharmacokinetics and addressing high production costs that previously halted its development.
The takeaway
Corramycin offers a potent new mechanism to neutralize resistant tuberculosis strains by locking the bacteria's own repair enzymes against them. Watch for upcoming announcements regarding the optimization of the drug's production and potential transition into preclinical pharmacokinetic trials.
Further reading
For more on the latest research in disease mitigation, visit Life Sciences.
More information
Review the complete scientific study publication in Advanced Science.
Live Poll
Do you believe natural compound research is the most promising path to curing drug-resistant diseases?
